Comparative Effectiveness of Enteral Nutrition and Immunomodulators in Inducing and Maintaining Remission in Pediatric Crohn's Disease: A Systematic Review and Network Meta-Analysis - Scorecard - MDSpire

Comparative Effectiveness of Enteral Nutrition and Immunomodulators in Inducing and Maintaining Remission in Pediatric Crohn's Disease: A Systematic Review and Network Meta-Analysis

  • By

  • Jiajia Chen

  • Keying Yang

  • Qiongyue Zhang

  • Lijing Xiong

  • April 22, 2026

  • 0 min

Share

Clinical Scorecard: Comparative Effectiveness of Enteral Nutrition and Immunomodulators in Inducing and Maintaining Remission in Pediatric Crohn's Disease: A Systematic Review and Network Meta-Analysis

At a Glance

CategoryDetail
Condition
Key MechanismsClarify the relationship between EN therapies and immunomodulators in the context of comparative effectiveness.
Target Population
Care Setting

Key Highlights

  • highlight_2

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Monitor clinical remission using validated scoring systems.
      • Assess mucosal healing through endoscopy at regular intervals.

      Risks

        Patient & Prescribing Data

        Pediatric patients with Crohn's disease.

        EEN and CDED + PEN are effective for inducing remission with lower adverse event rates.

        Clinical Best Practices

        • add

        References

        Original Source(s)

        Comparative Effectiveness of Enteral Nutrition and Immunomodulators in Inducing and Maintaining Remission in Pediatric Crohn's Disease: A Systematic Review and Network Meta-Analysis

        • by Jiajia Chen, Keying Yang, Qiongyue Zhang, Lijing Xiong

        • April 22, 2026

        Related Content

        Stabilized adaptive states in microbiome–human integrated physiology: reframing health and chronic disease as symbiotic biological states

        Context-dependent functions of ALKBH5: a mechanistic framework linking cellular stress responses, immune regulation, viral infection, and therapeutic vulnerabilities

        Therapeutic targets for diabetic nephropathy identified by druggable genome mendelian randomization: the role of the gut microbiota-metabolite axis